TL;DR
Digital health is no longer a side conversation in medtech. The FDA defines digital health broadly to include mobile health, wearable devices, telehealth, software, interoperability, wireless medical devices, and AI-enabled tools, and it has built a Digital Health Center of Excellence around responsible, high-quality innovation. For device teams, that means connected products now have to be designed as complete systems, with software, data flow, cybersecurity, usability, and lifecycle controls treated as core product requirements rather than late-stage add-ons. The companies that do this well are better positioned to support remote monitoring, earlier intervention, and more continuous care while avoiding the rework, submission delays, and scale-up problems that often appear when connectivity is approached too narrowly.
Why digital health has moved to the center of medtech
Digital health has matured from a promising category into a defining part of modern medical device strategy. The FDA describes the field as spanning mobile health, health IT, wearable devices, telehealth and telemedicine, and personalized medicine, and it notes that these technologies use computing platforms, connectivity, software, and sensors for healthcare uses. Just as important, the agency points to their potential to improve diagnosis, treatment, efficiency, prevention, and the management of chronic disease outside traditional care settings. In other words, digital health is not simply about adding an app or a wireless radio. It is about changing where care happens, how decisions are made, and what stakeholders expect from a device after it leaves the clinic.
That shift matters because connected devices increasingly live in environments that are messy, variable, and user-dependent. HHS defines remote patient monitoring as the use of digital devices to monitor a patient’s health and notes that it enables data collection and sharing between patients and providers. The FDA separately defines a home use device as one intended for users outside a professional healthcare facility. Together, those points frame a practical reality for medtech companies: many devices now need to perform reliably not just under controlled clinical workflows, but also in homes, community settings, and hybrid care models where connectivity, onboarding, training, and everyday usability can directly affect outcomes.
A common mistake is to treat this as a commercial trend rather than a design input. Teams may frame connectivity as a feature for differentiation, then discover late in development that the product actually depends on cloud architecture, data routing, user identity, interoperability, and human factors to work safely and effectively in the real world. At Pathway MedTech, we publicly position our support around integrated development, quality and regulatory, manufacturing, packaging, and sterilization, precisely because products become harder to commercialize when those disciplines are handled in isolation. That integration matters even more for connected and software-driven devices.
Connected devices are changing where care happens
The real promise of a connected device is not wireless capability by itself. It is the clinical and operational value created when information can move safely and be used meaningfully. The FDA defines medical device interoperability as the ability to safely, securely, and effectively exchange and use information among devices, technologies, or systems. It also notes that interoperable systems can improve patient care, reduce errors and adverse events, encourage innovation, and enable more diverse study datasets. That is why connectivity has become so important across remote monitoring, device ecosystems, hospital platforms, and hybrid care pathways. When a device can transmit, receive, interpret, or act on information across systems, it becomes part of a larger clinical workflow rather than a standalone tool.
What often gets missed is that this broader value also creates broader failure modes. If exchanged data is incomplete, delayed, mismatched, or misunderstood, the clinical experience can degrade quickly. Pairing problems, unclear alarm logic, weak labeling around network dependencies, and poorly defined behavior during loss of connectivity are not small annoyances. In a regulated product, they can become safety risks, usability issues, service burdens, and submission questions. This is especially relevant when devices are used outside clinical environments, where the FDA’s home use framing and its human factors guidance make it clear that intended users, intended uses, and intended use environments all matter.
For that reason, connected-device development should start with systems thinking. At Pathway MedTech, our publicly described five-phase development process and custom solutions capabilities emphasize early concept evaluation, risk identification, prototype refinement, and tighter coordination between development and regulated production. For connected products, that is where teams can surface practical issues early, before architecture decisions harden and before downstream verification work becomes more expensive.
Software is becoming the device experience
For many connected products, software is no longer supporting the device. It is shaping how the device is understood, regulated, updated, and used. The FDA defines Software as a Medical Device as software intended for one or more medical purposes that performs those purposes without being part of a hardware medical device. The agency also makes clear that its approach to device software functions is function-specific and applies across platforms. In practical terms, that means the mobile app, clinician dashboard, cloud logic, firmware layer, and analytics engine cannot be treated as secondary or interchangeable simply because some of them run on commercial hardware. If the software function meets the device definition or materially supports device performance, it affects regulatory expectations.
This has major implications for development strategy. FDA’s Medical Device Software Guidance Navigator is designed to help innovators identify relevant guidances across the software development lifecycle and align with eSTAR-related expectations. Its guidance on the content of premarket submissions for device software functions also underscores that software documentation is a core part of how the agency evaluates safety and effectiveness. A frequent mistake in connected-device programs is freezing the hardware concept while leaving app architecture, logging, software risk controls, and software documentation for later. That decision can ripple outward into verification scope, supplier controls, cybersecurity evidence, and even the basic question of whether the device’s intended use has been defined clearly enough.
Artificial intelligence makes that software reality even more consequential. The FDA maintains a public list of AI-enabled medical devices authorized for marketing in the United States, has published guiding principles for good machine learning practice, and finalized guidance in 2025 on Predetermined Change Control Plans for AI-enabled device software functions. The takeaway is not that every connected device should adopt AI. It is that the regulatory environment already expects manufacturers to think seriously about how software learns, changes, is validated, and is governed over time. Teams that underestimate this usually run into one of two problems: they oversell algorithmic ambition before they have the evidence and controls to support it, or they build useful software capability without a lifecycle strategy for updates, validation, and change management.
At Pathway MedTech, we publicly state that we can engage at any stage across design and engineering, regulatory, and manufacturing, and that our quality and regulatory team helps guide products through the development lifecycle. For connected devices, that kind of cross-functional coordination is not a nice-to-have. It is how teams avoid the very common trap of making software decisions that later complicate manufacturing, market clearance, or commercialization readiness.
Connectivity raises the bar for cybersecurity and usability
As connectivity expands value, it also expands responsibility. FDA’s February 2026 cybersecurity guidance provides recommendations on device design, labeling, and the documentation the agency recommends for premarket submissions for devices with cybersecurity risk, with the goal of helping ensure marketed devices are sufficiently resilient to cybersecurity threats. The FDA also explicitly notes that cybersecurity concerns rise with increasing interoperability. AAMI’s TIR57 further frames cybersecurity as a risk management issue in the context of ISO 14971. For medtech teams, the message is clear: cybersecurity is no longer a postmarket clean-up task or a problem to hand off to an IT group after launch. It is part of design, risk management, submission preparation, and lifecycle planning.
The most common cybersecurity mistake is to think about attack surfaces only after the product architecture is already fixed. By that point, decisions about communication protocols, authentication, update processes, third-party software, logging, and system boundaries may already be embedded in the design. Another common mistake is to document cybersecurity in a silo, disconnected from overall product risk management and labeling. That tends to create weak submissions and weak products because the safety case, user instructions, postmarket response planning, and technical controls are not written as one coherent story.
Usability is equally critical, especially as devices move into less controlled environments. FDA’s human factors guidance says manufacturers should follow usability engineering processes to maximize the likelihood that new devices are safe and effective for intended users, uses, and use environments, and to minimize use errors and resulting harm. That matters for connected devices because the user experience now includes more than a physical interface. It includes setup, pairing, login flow, alerts, app language, data presentation, and what the system does when something goes wrong. Companies often validate the device body carefully but give too little attention to the handoff between device, software, and user, particularly for home use. The downstream effect can be poor adoption, training burden, avoidable complaints, and a weaker clinical proposition even if the underlying technology performs well.
At Pathway MedTech, our public quality and regulatory materials emphasize lifecycle guidance and integrated planning, and our earlier cybersecurity thought leadership also acknowledges the joint responsibility of manufacturers and healthcare stakeholders in managing risk. For connected products, that mindset is the right one: resilience comes from combining product design, risk analysis, labeling, and operational discipline, not from any single technical control.
Building connected devices for regulatory and manufacturing reality
The future of connected medtech will not be won by the teams with the longest feature list. It will be won by the teams that can build repeatable, traceable, submission-ready systems. FDA’s Quality Management System Regulation became effective on February 2, 2026 and now incorporates ISO 13485:2016 as the foundational quality management system framework for medical device manufacturers. ISO describes ISO 13485 as an internationally recognized standard for medical device quality management systems, ISO 14971 describes risk management across the full lifecycle including data and systems security, and IEC 62304 establishes a common framework for medical device software lifecycle processes. Taken together, these are not abstract quality concepts. They are the operating backbone for turning a connected product into a regulated, manufacturable, maintainable device.
This is also where many promising programs lose time and money. A connected device may depend on sensors, radios, embedded software, app layers, cloud tools, data pipelines, packaging, sterilization, and qualified suppliers. If traceability is weak, if software versions are not controlled, if documentation trails are incomplete, or if manufacturing processes are still behaving like prototype experiments, the program becomes fragile right when evidence generation and commercialization planning are supposed to accelerate. Pathway’s public Device Verification materials describe DV builds as production-intent builds, not extended prototype runs, and stress full traceability, alignment with design controls and risk management, and documentation that becomes part of the regulatory record. That framing is exactly right for connected products, where small changes can have outsized downstream effects.
This is an area where we can help in concrete ways based on our publicly available capabilities. Pathway describes support across medical device development and manufacturing, device verification builds, low-volume manufacturing, ISO Class 7 cleanroom manufacturing, and supply chain development. We also describe GMP and ISO manufacturing support, packaging and sterile barrier support, production-transfer readiness, and documentation aligned to regulatory needs. For connected-device companies, that means assistance is available not only for design and regulatory planning, but also for the often-overlooked transition from functional prototype to controlled, scalable, commercialization-ready product.
What medtech teams should do now
The future of digital health and connected devices is not just more software, more sensors, or more data. It is more accountability across the full product lifecycle. Regulators are building clearer digital-health resources, software guidance, cybersecurity expectations, and quality-system alignment around that reality. The strategic implication for medtech leaders is straightforward: treat connectivity as a system-level product commitment. Define intended use early. Build software and interoperability architecture before they become expensive to change. Integrate cybersecurity and human factors into design controls. And make manufacturing, traceability, and supply chain readiness part of the conversation well before submission.
For teams navigating that path, Pathway publicly positions itself around integrated support from concept through commercialization, with capabilities spanning development, regulatory strategy, manufacturing, and case-study-backed execution across multiple device categories. That is the right place to add value in a market where connected products succeed or fail based on cross-functional coordination, not isolated excellence. The companies that recognize that early will be far better prepared for the next generation of digital medtech.
References
- FDA:Â What Is Digital Health?
- FDA:Â Digital Health Center of Excellence
- FDA:Â Medical Device Interoperability
- FDA:Â Design Considerations and Pre-market Submission Recommendations for Interoperable Medical Devices
- FDA:Â Device Software Functions Including Mobile Medical Applications
- FDA:Â Software as a Medical Device
- FDA:Â Artificial Intelligence-Enabled Medical Devices
- FDA:Â Good Machine Learning Practice for Medical Device Development
- FDA:Â Predetermined Change Control Plans for AI-Enabled Device Software Functions
- FDA:Â Content of Premarket Submissions for Device Software Functions
- FDA:Â Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions
- FDA:Â Quality Management System Regulation
- FDA:Â Applying Human Factors and Usability Engineering to Medical Devices
- FDA:Â Home Use Devices
- HHS:Â Telehealth and Remote Patient Monitoring
- ISO:Â ISO 13485
- ISO:Â ISO 14971
- IEC:Â IEC 62304
- AAMI:Â TIR57 Principles for Medical Device Security Risk Management
